1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
46 citations
,
September 2013 in “PLOS ONE” Thyrotropin-Releasing Hormone helps heal wounds in frog and human skin.
37 citations
,
June 2004 in “Human molecular genetics online/Human molecular genetics” The HCR gene contributes to psoriasis risk.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
45 citations
,
August 2005 in “Bioorganic & medicinal chemistry” New compounds with carborane showed anti-androgen effects similar to flutamide.
September 2025 in “Radboud University Press eBooks” AHR ligands could treat inflammatory skin diseases.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
January 2024 in “Bratislavské lekárske listy/Bratislava medical journal” Chloroquine and cinchonine relax rat blood vessels by affecting calcium channels, with chloroquine needing caution in heart patients.
15 citations
,
July 2022 in “Frontiers in Pharmacology” Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
3 citations
,
November 2024 in “Viruses” Cepharanthine may help treat Equid herpesvirus type 8 by reducing oxidative stress.
8 citations
,
August 2022 in “Pharmaceutics” Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
1 citations
,
December 2014 in “Journal of the Society of Cosmetic Scientists of Korea” CRF can cause hair loss, but blocking its receptors might prevent this.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
January 2009 in “Epsilon: Revista de la Sociedad Andaluza de Educación Matemática "Thales"” A CCS patient with severe complications was successfully treated using combined therapies.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
18 citations
,
March 2010 in “Gynecologic and obstetric investigation” The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.
4 citations
,
April 2022 in “Evidence-based Complementary and Alternative Medicine” Dracorhodin perchlorate helps heal wounds in diabetic rats by reducing inflammation.
March 2019 in “Reactions Weekly”
1 citations
,
August 2023 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” Kir6.1 mutations in Cantú syndrome increase channel sensitivity and hyperpolarization, while SUR2B mutations do not.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
June 2026 in “Current Oncology Reports” Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.